top of page

NOBROLA

A TWO-STAGE SIMON DESIGN PHASE II STUDY OF SINGLE AGENT OLAPARIB FOR NON-BRCA METASTATIC BREAST CANCER PATIENTS WITH HRD

TO EVALUATE OLAPARIB IN ADVANCED TRIPLE NEGATIVE BREAST CANCER (TNBC) PATIENTS WITH HOMOLOGOUS RECOMBINATION DEFICIENCY (HRD) AND NO GERMLINE BRCA1/2 MUTATIONS (gBRCA1/2mut).

https://clinicaltrials.gov/study/NCT02789332

COUNTRY

STATUS

TUMOR TYPE

PHASE

N

SITES

Triple-Negative Breast Cancer

17

114 (6 eligible/treated)

IIa

Spain

Completed

CLINICAL TRIAL DETAILS

PRESS RELEASE

home_fondo_you_barra.jpg

​

SCIENTIFIC IMPACT

home_fondo_you_barra.jpg

The Breast 2024 publication: https://www.thebreastonline.com/article/S0960-9776(24)00165-6/fulltext

BLOG ARTICLES RELATED

home_fondo_you_barra.jpg

Spotlight – NOBROLA trial for advanced triple-negative breast cancer: https://www.medsir.org/post/spotlight-nobrola-trial-for-advanced-triple-negative-breast-cancer

TRIAL SITES

home_fondo_you_barra.jpg
Dr. Cortes and Dr. Llombart PHERain interview
Beyond Chemotherapy
Dr. Vanes Quiroga
Dr. Sofia Braga
Dr. Silvi Antolín
Dr. Escrivá de Romaní
Dr. Philipp Aftimos
Dr. Manuel Ruiz
Prof. Daniele Generali PHEGain interview
Dr. Jacques Medioni
Dr. Dunca Wheatley
bottom of page